Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311349 | 0.90 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL31060758 | 0.89 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL2724877 | 0.89 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14845989 | 0.84 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL11718350 | 0.83 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14846012 | 0.83 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14846008 | 0.83 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL11768171 | 0.81 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL11721660 | 0.81 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14846011 | 0.81 | PLD2 (1.00) | PLD2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-20160296506-A1 | Methods and Compositions for Treating HIV Infection | VANDERBILT UNIVERSITY | 2016-10-13 | — | — | US | disclosed |
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140378524-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| WO-2014093553-A1 | METHODS AND COMPOSITIONS OF TREATING HIV INFECTION | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014093557-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163055-A1 | METHODS AND COMPOSITIONS OF TREATING HIV INFECTION | VANDERBILT UNIVERSITY | 2014-06-12 | — | — | US | disclosed |
| WO-2013049773-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378524-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | PLD2 2/4885PLD1 1/4885 |
| US-20160296506-A1 | Methods and Compositions for Treating HIV Infection | SMPD3, PLD3, SMPD1 | PLD2 5/4885PLD1 4/4885 |
| US-20140163055-A1 | METHODS AND COMPOSITIONS OF TREATING HIV INFECTION | PLD3, SMPD3, SMPD1 | PLD2 5/4885PLD1 4/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | PLD2 2/4885PLD1 1/4885 |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | PLD1, PLA2G2D, PLD2 | PLD2 3/4885PLD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.